Phoenix Holdings Ltd. purchased a new position in shares of Allergan plc (NYSE:AGN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 92,159 shares of the company’s stock, valued at approximately $14,796,000.
Other large investors have also recently added to or reduced their stakes in the company. Prestige Wealth Management Group LLC acquired a new stake in Allergan in the second quarter valued at about $25,000. Old North State Trust LLC lifted its position in shares of Allergan by 172.4% during the 3rd quarter. Old North State Trust LLC now owns 158 shares of the company’s stock valued at $27,000 after acquiring an additional 100 shares during the period. Reilly Financial Advisors LLC lifted its position in shares of Allergan by 129.3% during the 3rd quarter. Reilly Financial Advisors LLC now owns 172 shares of the company’s stock valued at $29,000 after acquiring an additional 97 shares during the period. Motco acquired a new stake in shares of Allergan during the 2nd quarter valued at approximately $29,000. Finally, HM Payson & Co. acquired a new stake in shares of Allergan during the 2nd quarter valued at approximately $29,000. Institutional investors own 81.93% of the company’s stock.
A number of research firms have recently issued reports on AGN. Royal Bank of Canada reiterated a “hold” rating and set a $178.00 price target on shares of Allergan in a research report on Thursday, August 8th. ValuEngine cut shares of Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, October 30th. Barclays raised their price objective on shares of Allergan from $176.00 to $188.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 7th. Wells Fargo & Co reissued an “outperform” rating and set a $184.00 price objective (up from $176.00) on shares of Allergan in a research note on Monday, September 30th. Finally, Guggenheim cut shares of Allergan from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $175.90.
Allergan (NYSE:AGN) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $4.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $4.25. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. The business had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $3.88 billion. During the same quarter in the prior year, the firm earned $4.25 EPS. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. Equities research analysts predict that Allergan plc will post 16.89 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Wednesday, November 13th will be given a $0.74 dividend. This represents a $2.96 annualized dividend and a yield of 1.59%. The ex-dividend date of this dividend is Tuesday, November 12th. Allergan’s dividend payout ratio (DPR) is 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: How Does the Quiet Period Work?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.